Highland Capital Management (Texas)’s Acadia Pharmaceuticals ACAD Stock Holding History

Highland Capital Management (Texas)’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-25,300	Closed	-$679K	–	314
2019 Q1	$679K	Buy	+25,300	New	+$591K	0.04%	228
2017 Q2	–	Sell	-26,200	Closed	-$901K	–	290
2017 Q1	$901K	Buy	26,200 +6,200	+31%	+$219K	0.05%	198
2016 Q4	$577K	Buy	+20,000	New	+$529K	0.03%	215
2014 Q2	–	Sell	-67,833	Closed	-$1.65M	–	264
2014 Q1	$1.65M	Buy	67,833 +22,833	+51%	+$578K	0.07%	136
2013 Q4	$1.13M	Buy	+45,000	New	+$1.06M	0.06%	108

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Highland Capital Management (Texas)'s ACAD Position: Q2 2019 in Review

Highland Capital Management (Texas) sold out of Acadia Pharmaceuticals (ACAD) in Q2 2019, closing a stake of 25,300 shares — an estimated $679K sold.

Highland Capital Management (Texas) first reported a position in ACAD in Q4 2013 and held it in 5 quarters. The position peaked at $1.65M in Q1 2014. 196 funds tracked by Wall St. Rank hold ACAD as of Q2 2019.

Highland Capital Management (Texas) reported no remaining Acadia Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Highland Capital Management (Texas) sold 25,300 Acadia Pharmaceuticals shares in Q2 2019, an estimated $679K.
Highland Capital Management (Texas) first reported a position in Acadia Pharmaceuticals in Q4 2013 and held it in 5 quarters.
Highland Capital Management (Texas)'s Acadia Pharmaceuticals position peaked at $1.65M in Q1 2014.
196 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2019.

Based on Highland Capital Management (Texas)'s 13F filing for Q2 2019, filed 14 Aug 2019.